Stock Analiz

Tonix Pharmaceuticals Holding Corp. TNXP

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$3.01Market cap $58M
Open the interactive analysis →

Tonix Pharmaceuticals Holding Corp. (TNXP) is a healthcare company listed in the US with a market value of about $58M. In the twelve months to September 30, 2026 it had revenue of $43M and net income of -$181M, a net margin of -420.4%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -54%.

About Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 313177% over three years (dilution for shareholders). It spends 339% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.4
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-290.7%
Shareholder yield23.5%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)29.8%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1245.4%
ROIC (5-yr avg.)-53.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$43M$13M$10M$8M———————
Net income-$181M-$124M-$130M-$117M-$110M-$92M-$50M-$29M-$26M-$21M-$39M
Free cash flow-$170M-$103M-$61M-$110M-$146M-$111M-$57M-$27M-$24M-$19M-$37M
EPS (diluted)$-12.41$-14.57$-176.60$-14720.25$-43022.91$-106551.70$-7234.99$-254277.08$-3418204.78$-416867.08$-2027113.47
Net margin-420.4%-946.2%-1288.2%-1501.8%———————
ROIC—-40.3%-72.6%-79.6%-42.6%-33.2%-44.9%-233.0%-87.9%-68.3%-121.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $34.00, 1030% above the current price; targets range from $18.00 to $64.00; the consensus rating is “Strong buy”; expected EPS is $-10.91 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Tonix Pharmaceuticals Holding pay a dividend?

Not currently.

Is Tonix Pharmaceuticals Holding a good stock to buy?

We do not give buy or sell advice. Tonix Pharmaceuticals Holding scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.